In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Alexander Drilon, MD, faculty for this educational event, received honoraria and advisory board fees from Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, I3 Health, MonteRosa, Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, JNCC/Harborside, and Lungevity ; and is a patent holder for TreelineBio; and receives research funds from Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar, Selpercatinib-Osimertinib (filed/pending), and Foundation Medicine and; receives royalties from Wolters Kluwer.
Justin Gainor, MD, faculty for this educational event, received an honorarium and advisory fees from Pfizer, Novartis, Takeda, AstraZeneca, Merck, Gilead, Genentech/Roche, Bristol-Myers Squibb, Ariad/Takeda, Genentech/Roche, Loxo/Lilly, Mirati, Moderna, Blueprint, Amgen, Agios, Regeneron, Oncorus, GlydeBio, iTeos, Karyopharm, Roche, and Takeda; and received research funds from Novartis, Genentech, Takeda, Tesaro, Moderna, Blueprint, Bristol-Myers Squibb, Jounce, Array Biopharma, Adaptimmune, Novartis, Alexo, and Merck; and received ownership interest from Ironwood Pharmaceuticals (Immediate family member).